{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:54:40Z","timestamp":1785898480990,"version":"3.56.0"},"reference-count":46,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Background: Functioning gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are rare tumors that secrete biologically active hormones, leading to complex clinical syndromes such as carcinoid syndrome, VIPoma, glucagonoma, gastrinoma, insulinoma, and somatostatinoma. These syndromes frequently induce profound metabolic, gastrointestinal, and nutritional disturbances. Objective: This review aims to provide a comprehensive overview of the physiopathology of malnutrition in functioning GEP-NENs and to highlight nutritional and supportive care strategies, including how medical, surgical, and locoregional treatments can indirectly improve nutritional outcomes. Methods: We analyzed the current literature and clinical guidelines to identify key mechanisms of malnutrition across different functioning syndromes and their clinical manifestations. Nutritional recommendations and the impact of treatment modalities on nutritional status were summarized. Results: The pathophysiology of malnutrition in functioning NENs is multifactorial and syndrome-specific. Hormonal hypersecretion may cause diarrhea, electrolyte imbalances, catabolic states, steatorrhea, or hypoglycemia, among other effects. These lead to nutrient loss, malabsorption, or altered intake. Tailored dietary interventions, micronutrient supplementation (e.g., niacin, calcium, vitamin B12), and symptom-guided nutritional support are essential. Somatostatin analogs, PRRT, and cytoreductive approaches often contribute to symptom control, thereby enhancing nutritional status and patient quality of life. Conclusions: Malnutrition in functioning GEP-NENs is a significant clinical issue that requires early recognition and a multidisciplinary, individualized management plan. Integrating nutrition into the comprehensive care of these patients is essential to improve outcomes and quality of life.<\/jats:p>","DOI":"10.3390\/nu17132175","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T06:18:36Z","timestamp":1751264316000},"page":"2175","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nutritional Management of Functioning GEP-NENs"],"prefix":"10.3390","volume":"17","author":[{"given":"Maribel","family":"del Olmo-Garc\u00eda","sequence":"first","affiliation":[{"name":"Joint Research Unit on Endocrinology, Nutrition and Clinical Dietetics, Research Institute La Fe, University of Valencia-Health, 46026 Valencia, Spain"},{"name":"Department of Medicine, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain"},{"name":"Department of Endocrinology and Nutrition, University and Polytechnic Hospital La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Hernandez-Rienda","sequence":"additional","affiliation":[{"name":"Joint Research Unit on Endocrinology, Nutrition and Clinical Dietetics, Research Institute La Fe, University of Valencia-Health, 46026 Valencia, Spain"},{"name":"Department of Endocrinology and Nutrition, University and Polytechnic Hospital La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Argente Pla","sequence":"additional","affiliation":[{"name":"Joint Research Unit on Endocrinology, Nutrition and Clinical Dietetics, Research Institute La Fe, University of Valencia-Health, 46026 Valencia, Spain"},{"name":"Department of Endocrinology and Nutrition, University and Polytechnic Hospital La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0191-4504","authenticated-orcid":false,"given":"Juan F.","family":"Merino-Torres","sequence":"additional","affiliation":[{"name":"Joint Research Unit on Endocrinology, Nutrition and Clinical Dietetics, Research Institute La Fe, University of Valencia-Health, 46026 Valencia, Spain"},{"name":"Department of Medicine, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain"},{"name":"Department of Endocrinology and Nutrition, University and Polytechnic Hospital La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases","volume":"26","author":"Yao","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"oyae343","DOI":"10.1093\/oncolo\/oyae343","article-title":"Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: The NUTRIGETNE (GETNE-S2109) study","volume":"30","author":"Hernando","year":"2025","journal-title":"Oncologist"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol."},{"key":"ref_5","first-page":"iv131","article-title":"Impact of nutritional status in patients with neuroendocrine tumors","volume":"27","author":"Cwikla","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_6","first-page":"744","article-title":"Management of patients with advanced neuroendocrine tumors: The role of nutrition and supportive care","volume":"41","author":"Yao","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11154-018-9466-z","article-title":"Nutrition and neuroendocrine tumors: An update of the literature","volume":"19","author":"Altieri","year":"2018","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_8","first-page":"225","article-title":"Malnutrition predicts clinical outcome in patients with neuroendocrine neoplasms","volume":"27","author":"Maasberg","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_9","first-page":"2585","article-title":"Nutritional support in cancer patients: Results of a survey among Italian oncologists","volume":"24","author":"Caccialanza","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clnu.2018.08.002","article-title":"GLIM criteria for the diagnosis of malnutrition\u2014A consensus report from the global clinical nutrition community","volume":"38","author":"Cederholm","year":"2019","journal-title":"Clin. Nutr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.clnu.2017.06.017","article-title":"ESPEN expert group recommendations for action against cancer-related malnutrition","volume":"36","author":"Arends","year":"2017","journal-title":"Clin. Nutr."},{"key":"ref_12","first-page":"1054","article-title":"Ponsegromab, a GDF15-neutralizing antibody, improves body weight and lean mass in cancer cachexia: Early clinical insights","volume":"14","author":"Na","year":"2023","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000443171","article-title":"ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors","volume":"103","author":"Falconi","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref_14","first-page":"f5636","article-title":"Carcinoid syndrome","volume":"347","author":"Khan","year":"2013","journal-title":"BMJ"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1200\/JCO.2014.60.2532","article-title":"Carcinoid and neuroendocrine tumors: Building on success","volume":"33","author":"Kunz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_16","first-page":"171","article-title":"Neuroendocrine tumor-associated malnutrition and the role of nutritional therapy: A narrative review","volume":"49","author":"Megerle","year":"2022","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_17","first-page":"246","article-title":"The role of diet in managing carcinoid syndrome","volume":"68","author":"Davies","year":"2016","journal-title":"Nutr. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Clement, D.S.V.M., Brown, S.E., Naghibi, M., Cooper, S.C., Tesselaar, M.E.T., van Leerdam, M.E., Ramage, J.K., and Srirajaskanthan, R. (2023). Feasibility of Home Parenteral Nutrition in Patients with Intestinal Failure Due to Neuroendocrine Tumours: A Systematic Review. Nutrients, 15.","DOI":"10.3390\/nu15173787"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Octreotide LAR in metastatic neuroendocrine midgut tumors","volume":"27","author":"Rinke","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_21","first-page":"712","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumors","volume":"29","author":"Pavel","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome diarrhea in patients with neuroendocrine tumors: A randomized, double-blind, placebo-controlled, phase 3 trial","volume":"35","author":"Kulke","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_23","first-page":"659","article-title":"Management of carcinoid syndrome","volume":"47","author":"Howe","year":"2018","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e13146","DOI":"10.1111\/jne.13146","article-title":"European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease","volume":"34","author":"Davar","year":"2022","journal-title":"J. Neuroendocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NENs)","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2967\/jnumed.119.240911","article-title":"NANETS\/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy","volume":"61","author":"Hope","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_27","first-page":"1411","article-title":"VIPoma: A rare neuroendocrine tumor","volume":"8","author":"Goyal","year":"2020","journal-title":"World J. Clin. Cases"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0002-9343(87)90425-6","article-title":"VIPoma syndrome","volume":"82","author":"Krejs","year":"1987","journal-title":"Am. J. Med."},{"key":"ref_29","first-page":"723","article-title":"Management of VIPoma","volume":"47","author":"Howe","year":"2018","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_30","first-page":"1940","article-title":"Pancreatic neuroendocrine tumors: Treating VIPomas and other functioning tumors","volume":"123","author":"Arnaoutakis","year":"2021","journal-title":"J. Surg. Oncol."},{"key":"ref_31","first-page":"168","article-title":"Electrolyte disturbances in neuroendocrine tumors: Management strategies","volume":"50","author":"Giuliani","year":"2022","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_32","first-page":"4716","article-title":"Nutritional aspects of neuroendocrine tumors","volume":"23","author":"Pereira","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/MPA.0000000000001454","article-title":"The North American Neuroendocrine Tumor Society consensus guidelines for the diagnosis and management of neuroendocrine tumors: Pheochromocytoma, paraganglioma, and functional and nonfunctional pancreatic neuroendocrine tumors","volume":"49","author":"Howe","year":"2020","journal-title":"Pancreas"},{"key":"ref_34","first-page":"112","article-title":"Epidemiology, clinical features and diagnosis of glucagonoma: A comprehensive review","volume":"23","author":"Tomassetti","year":"2001","journal-title":"Pancreas"},{"key":"ref_35","first-page":"13030","article-title":"Zinc deficiency in glucagonoma syndrome: A review of literature","volume":"27","author":"Chandrasekaran","year":"2021","journal-title":"Dermatol. Online J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000335591","article-title":"Gastrinoma (Zollinger-Ellison syndrome): An ENETS consensus guideline","volume":"95","author":"Jensen","year":"2012","journal-title":"Neuroendocrinology"},{"key":"ref_39","first-page":"647","article-title":"Gastrinomas: Advances in treatment","volume":"29","author":"Lamberts","year":"2000","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_40","first-page":"37","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced metastatic gastrinoma: Case series and literature review","volume":"45","author":"Delpassand","year":"2020","journal-title":"Clin. Nucl. Med."},{"key":"ref_41","first-page":"165","article-title":"Somatostatinoma: Clinical features and therapeutic strategies","volume":"40","author":"Modlin","year":"2011","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_42","unstructured":"Feingold, K.R., Ahmed, S.F., Anawalt, B., Blackman, M.R., Boyce, A., Chrousos, G., Corpas, E., de Herder, W.W., Dhatariya, K., and Dungan, K. (2013). Insulinoma. Endotext, MDText.com, Inc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1210\/clinem\/dgad641","article-title":"Approach to the Patient: Insulinoma","volume":"109","author":"Hofland","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_44","first-page":"481","article-title":"Clinical use of continuous glucose monitoring in non-diabetic conditions: Emerging evidence and applications","volume":"45","author":"Adalsteinsson","year":"2022","journal-title":"J. Endocrinol. Investig."},{"key":"ref_45","first-page":"321","article-title":"Real-time continuous glucose monitoring system for the detection of insulinoma in patients with hypoglycemia","volume":"29","author":"Chae","year":"2014","journal-title":"Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Masciangelo, G., Campana, D., Ricci, C., Andrini, E., Rakichevikj, E., Fusaroli, P., and Lisotti, A. (2025). Endoscopic Ultrasound-Guided Locoregional Treatments for Pancreatic Neuroendocrine Neoplasms. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32020113"}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/13\/2175\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:01:47Z","timestamp":1760032907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/13\/2175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":46,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["nu17132175"],"URL":"https:\/\/doi.org\/10.3390\/nu17132175","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}